Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
NNX 0.035 +0.0% ABX 51.79 −0.8% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.12 +11.2% TUNG 1.72 +1.8% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.43 +0.0% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.315 −1.6% DEX 0.390 +1.3% WMS 0.040 +0.0% NNX 0.035 +0.0% ABX 51.79 −0.8% TTS 2.50 +0.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.12 +11.2% TUNG 1.72 +1.8% LGO 1.00 −3.9% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.43 +0.0% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.315 −1.6% DEX 0.390 +1.3% WMS 0.040 +0.0%
Other Routine +

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT(TM) at ASCO 2026

ASCO Data Confirms Survival Benefit Amidst Dilution Headwinds

By The Northwire Desk — AI Analysis May 22, 2026 · 07:30 BCT · 5.05 BRIACELL THERAPEUTICS CORP. J
Executive Summary
  • BriaCell Therapeutics presented positive clinical data for its lead candidate Bria-IMT at the 2026 ASCO Annual Meeting.
  • Phase 2 data for the formulation selected for Phase 3 trials demonstrated a median overall survival (OS) of 16.6 months and a 52% survival rate at 12 months.
  • Ongoing Phase 3 study data indicates preservation of quality of life in heavily pre-treated patients and supports potential home self-administration.
  • New biomarker analyses identified circulating tumor cells (CTCs), delayed-type hypersensitivity (DTH) positivity, and Cancer-Associated Macrophage-Like cells (CAMLs) as predictors of clinical response.
  • The company continues to expand its pipeline with Bria-OVA+ for ovarian cancer and Bria-PROS+ for prostate cancer, leveraging the same platform technology.
Material Impact
  • Anticipation: The data presentation was announced in April 2026 (NewsId 1115235), making the release itself expected rather than a surprise catalyst.
  • Validation vs. New Information: The survival metrics (16.6 months OS) confirm and slightly improve upon previous Phase 2 announcements (median OS 13.4 months reported in Jan 2026). This validates the thesis but does not fundamentally alter the risk profile of the binary Phase 3 readout expected in H1 2026.
  • Market Context: The stock has already declined ~87% from its June 2025 highs due to a $30 million dilutive financing event in January 2026. Positive clinical data is often insufficient to reverse sentiment driven by capital structure concerns without regulatory approval or top-line Phase 3 results.
  • Conclusion: The news reinforces the company's pipeline progress but lacks the "unexpected" element required for a Material - Positive rating given the prior announcements and current market pricing of dilution risk.
BCT · Price
Company Overview
  • Company: BriaCell Therapeutics Corp. focuses on personalized, off-the-shelf cell-based immunotherapies.
  • Flagship Project: Bria-IMT (Bria-OTS+ platform) for metastatic breast cancer (MBC).
  • Development Status: Pivotal Phase 3 study (Bria-ABC) is ongoing; FDA Fast Track designation granted.
  • Pipeline Expansion: Recent additions include Bria-OVA+ (ovarian cancer), Bria-PROS+ (prostate cancer), and BC1 (second-generation immunotherapy).
  • Platform Technology: Utilizes the Bria-OTS+ platform designed to activate both adaptive and innate immunity, including T cells, dendritic cells, and NK cells.
Read the original news release →

More from BRIACELL THERAPEUTICS CORP. J

Jun 25, 2026 · 07:30

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT(TM)

M&A / Property Jun 02, 2026 · 16:05

BriaCell Closes $4.7M Discounted Offering as Pre-Revenue Burn Rate Demands Cash, Dilution Weighs on Sentiment

Financings Jun 01, 2026 · 07:30

BriaCell’s ASCO Data Validates Pipeline Trajectory, But Dilutive Capital Raise and Phase 3 Event-Driven Timeline Keep Near-Term Upside Capped

Other May 31, 2026 · 19:59

BriaCell Therapeutics Announces Pricing of Offering

Financings May 31, 2026 · 03:20

Briacell prices shares of $4.7M offering at $3.25 each

Financings May 26, 2026 · 07:30

Safety Confirmed but Efficacy Uncertainty Weighs on Valuation Amidst Dilution Concerns

Other